COVAXX, a subsidiary of United Biomedical, Inc. (UBI), announced Monday that its vaccine for COVID-19, UB-612, has induced neutralizing antibodies in 100% of the participants during the phase 1 clinical trial, as reported by Reuters.
“UB-612 was generally well tolerated and had a reassuring safety profile“, the company has also pointed out.”All subjects developed neutralizing antibodies after two doses of the vaccine“.
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
